Home » Economy » Merck announces that the protection of the latest experimental data of the new crown oral drug has dropped from 50% to 30% | Anue Juheng-US Stocks

Merck announces that the protection of the latest experimental data of the new crown oral drug has dropped from 50% to 30% | Anue Juheng-US Stocks

American pharmaceutical giant Merck (Merck & Co., Ltd.) announced on Friday (26th) the latest analysis of experimental new crown oral administration. The results show that the protection against severe illness and death is 30%, which is lower than the approximately 50% announced in October. Merck (MRK-US) The stock fell 3.8%.

The latest analysis has a major impact on whether other countries continue to purchase Merck’s drug. The United Kingdom has approved the drug in early November. The drug is called “molnupiravir” (molnupiravir), developed by Merck and Ridgeback Biotherapeutics, the latest analysis is for the analysis of 1433 patients, and October is the analysis of the number of 775 patients.

Pfizer (PFE-US) Data from the mid-term trial of its experimental new crown oral drug “Paxlovid” shows that the risk of severe illness and death can be significantly reduced by 89%. The experiment has a total of 1,200 participants.

Merck’s stock price fell on Friday and fell 3.79% to 79.16 per share Dollar

The U.S. Food and Drug Administration (FDA) external expert team plans to discuss next Tuesday whether to authorize the use of the drug. The discussion includes whether the use of the drug has more advantages than disadvantages, whether it is limited to specific ethnic groups, and whether drug resistance develops.

FDA officials publicly released the results of the preliminary review on Friday, saying that molnupiravir effectively reduces the risk of hospitalization and severe illness, and there are no major safety concerns in the late trials.

Compared with the existing antibody therapies of Regeneron and Eli Lilly, Merck and Pfizer’s new crown oral drugs are cheaper to produce and simpler to dispense. The mechanism of operation of the two drugs is different. Merck’s molnupiravir causes errors in the viral gene coding, and Pfizer’s Paxlovid tries to block the enzymes necessary for the propagation of the virus.

Merck currently expects to produce 10 million COVID-19 oral medicines by the end of the year, increasing to at least 20 million in 2022. The company has agreed with the U.S. government to set a price of 700 DollarAs many as 5 million copies have been supplied, and other countries have already purchased millions of copies.


Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.